<DOC>
	<DOCNO>NCT00268879</DOCNO>
	<brief_summary>The purpose study investigate whether renzapride help alleviate symptom associate constipation predominant irritable bowel syndrome female patient .</brief_summary>
	<brief_title>Investigation Safety Efficacy Renzapride Constipation Predominant Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description>Irritable bowel syndrome ( IBS ) chronic gastrointestinal disorder characterize recurrent symptom abdominal pain/discomfort accompany disturbed bowel function . In study female patient constipation predominant IBS receive one two dosing regimen renzapride placebo 12 week . Patients record severity symptom throughout study . The result analyse see patient receive renzapride great relief symptom patient receive placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Renzapride</mesh_term>
	<criteria>Females constipation predominant IBS define Rome II criterion Colonoscopy sigmoidoscopy previous 5 year show significant disease Patients diarrhoea predominant alternate symptom IBS Other gastrointestinal disease affect bowel transit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Irritable bowel syndrome</keyword>
	<keyword>Constipation-predominant irritable bowel syndrome</keyword>
</DOC>